Janux Therapeutics JANX
NASDAQ JANX
$12.39 +0.35 (+2.91%)
At close: Nov 11, 2026 · 4:00 PM EST

Janux Therapeutics (JANX) Return on Sales [ROS] (2021 - 2026)

Updated

Janux Therapeutics (JANX) recorded Return on Sales [ROS] of -308.66% in Q2 2026, up 32693.39 percentage points from -33002.05% a year earlier and up 607.84 percentage points from the prior quarter.

Analysis

Janux Therapeutics (JANX) Return on Sales [ROS] (2021 - 2026) Analysis & Trends

On a TTM basis, Janux Therapeutics' Return on Sales [ROS] came in at -598.15% as of Jun 30, 2026, up 32403.90 percentage points year-over-year; for FY2025, it came in at -1576.67%, down 643.09 percentage points from FY2024.

  • Annual Return on Sales [ROS] has declined for three straight years, with a four-year change of -671.28 percentage points (FY2021 to FY2025).
  • Across earlier years, Return on Sales [ROS] came in at -933.58% in FY2024 (-30.71 pp), -902.87% in FY2023 (-123.83 pp), -779.04% in FY2022 (+126.35 pp) and -905.39% in FY2021.
  • The Q2 2026 figure is the highest quarterly Return on Sales [ROS] since Q2 2024.
  • On a year-over-year basis, Return on Sales [ROS] rose in four of the last eight quarters, with an average year-over-year change of -13.09 percentage points.
  • Peak year-over-year performance for Return on Sales [ROS] in the last five years was a gain of 32693.39 percentage points in Q2 2026, against a drop of 32846.69 percentage points in Q2 2025 at the low end.
  • Per Business Quant, the preceding three quarters came in at -916.50% (Q1 2026), -1576.67% (Q4 2025) and -352.51% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 Janux Therapeutics 736.54 Mn -3.10 Bn - -336.51%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -336.51%
Jun 30, 2026 -308.66%
Mar 31, 2026 -916.50%
Dec 31, 2025 -1,576.67%
Sep 30, 2025 -352.51%
Jun 30, 2025 -33,002.05%
Mar 31, 2025 -1,216.61%
Dec 31, 2024 -933.58%
Sep 30, 2024 -8,164.46%
Jun 30, 2024 -155.36%
Mar 31, 2024 -1,610.30%
Dec 31, 2023 -655.71%
Sep 30, 2023 -628.25%
Jun 30, 2023 -1,962.91%
Mar 31, 2023 -990.28%
Dec 31, 2022 -642.04%
Sep 30, 2022 -994.04%
Jun 30, 2022 -729.85%
Mar 31, 2022 -852.23%
Dec 31, 2021 -834.78%
API Access

Janux Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=JANX&period=max&api_key=YOUR_API_KEY